Table 2.
Plant name | Plant part | Study design | Number of patients | Duration of treatment | Results | Type of IBD | Study |
---|---|---|---|---|---|---|---|
Artemisia absinthium | Powder | Placebo-controlled, double-blind trial | 40 | 10 weeks | Complete remission in 65% of plants group in comparison to no remission in placebo group | CD | Micallef et al.[30] |
Aloe vera | Gel | Placebo-controlled, double-blind trial | 44 | 4 weeks | Clinical remission in 9, improvement in 11, and good response in 14 patients on aloe group in comparison to 1, 1 and 2 patients in placebo group, respectively. Also significant improvement in histological scores and index of clinical colitis activity in aloe group | UC | Langmead et al.[72] |
Triticum aestivum | Grass juice | Placebo-controlled, double-blind trial | 23 | 4 weeks | Significant improvement in severity of rectal bleeding and disease activity index. No serious side effects | UC | Ben-Arye et al.[73] |
Andrographis paniculata | Extract | Placebo-controlled, double-blind trial | 101 | 8 weeks | Significant reduction in the mean CRP level in 8th week in patients who received extract in comparison to placebo group | CD | Sandborn et al.[74] |
Plantago Ovata | Seed | Open-label, parallel group, randomized | 105 | 12 months | Same as mesalamine in maintenance of remission | UC | Rodríguez-Cabezas et al.[75] |
Boswellia serrata | Powder | Open-label, parallel group, randomized | 30 | 6 weeks | Improvement in more than one parameter such as stool properties in Boswellia group | UC | Gupta et al.[76] |
Oenothera biennis | Oil | Placebo-controlled | 43 | 6 months | Stool consistency improved and also was maintained even when the treatment discontinued | UC | Greenfield et al.[77] |
Curcuma longa | Extract | Placebo-controlled, double-blind trial | 89 | 6 months | A marked decrease in endoscopic index and the index of disease-associated clinical activity | UC | Algieri et al.[78] |
CD=Crohn’s disease; UC=Ulcerative colitis; IBD=Inflammatory bowel disease